NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
– Combines NewAmsterdam’s lead clinical program obicetrapib with Menarini’s deep cardiovascular disease and regional expertise – Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe – Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor for […]